ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma. The company was founded in 2015 and is based in Burlingame, California. The company trades on NASDAQ exchange. The company headquarter is located in Burlingame, California. The company was established in the 2015.

TickerALXO
Long NameALX Oncology Holdings Inc.
Short NameALX Oncology Holdings